25 Documents disponibles écrits par cet auteur
2-(Methylamino)-1-(2-methylphenyl)propan-1-one (2-methylmethcathinone, 2-MMC) is a synthetic cathinone monitored by the EUDA as a new psychoactive substance through the European Union Early Warning System. Based on potential public health risks,[...]
1-(4-Bromophenyl)-2-(methylamino)propan-1-one (4-bromomethcathinone, 4-BMC) is a synthetic cathinone monitored by the EUDA as a new psychoactive substance through the European Union Early Warning System. Based on potential public health risks, a[...]
This threat assessment presents a scenario-based analysis of the potential risks posed by highly potent synthetic opioids (HPSOs) in Europe over the next two years. Drawing on available early warning signals, forensic and clinical data, and expe[...]
Cannabis remains the most widely used illicit drug in Europe. Our updated miniguide explores key health and social risks associated with its use, alongside evidence-based approaches to prevention, treatment and harm reduction across Europe. This[...]
Cocaine markets have the potential to generate environmental harms that extend far beyond deforestation, affecting water, soil, air quality and biodiversity across multiple regions and cocaine-related activities. This joint report by the Europea[...]
Background and introduction: While evidence from drug treatment centres suggests that injecting drug use is declining among heroin clients in the European Union, the risk of overdose death and infectious diseases associated with this mode of adm[...]
Illicit drug production in the European Union is a persistent and evolving phenomenon, encompassing a wide range of substances and production methods. The EUDA supports EU-level understanding of illicit drug production by bringing together infor[...]
This technical protocol outlines the key steps and considerations to be taken when deciding whether and how to set up a survey for monitoring DRID, related risk factors and preventive interventions among people who inject drugs (PWID). [Editor's[...]
Co-occurring mental health and substance use disorders ('dual disorders') are a key concern for policy and service planning in Europe, prompting calls for more integrated and coordinated care systems. This [...] miniguide [...] explores how Euro[...]
"EU Drug Market: MDMA" describes the European MDMA market from production to trafficking, distribution and use. It details the materials, processes and players involved at different stages and levels of the market. The module takes a threat asse[...]
On this page you can explore data from the hospitals participating in the European Drug Emergencies Network (Euro-DEN - Euro-DEN Plus) project. Since 2013, the project has been collecting data on acute drug toxicity presentations in an expandin[...]
FRANÇAIS : Les changements rapides sur le marché européen des drogues créent de nouveaux risques pour la santé et la sécurité. Ils mettent à l'épreuve la capacité de la région à y faire face. Cette mise en garde émane de l'Agence de l'Union eur[...]
Les consommateurs de drogues en Europe sont confrontés à de nouveaux risques sanitaires, alors que les marchés évoluent rapidement et se complexifient. S'appuyant sur les données de 29 pays (UE-27, Norvège et Turquie), ce rapport annuel met en[...]
This data factsheet presents insights from the European Web Survey on Drugs 2024. It provides an overview of key data from 61 732 individuals aged 18 or older who use drugs and live in one of 24 EU countries or Norway. The survey was conducted a[...]
This page provides answers to the questions most often asked about drug overdose deaths in Europe. Also known as 'drug-related deaths' or more specifically 'drug-induced deaths', they are deaths directly attributable to the use of illicit drugs.[...]
Historique
